Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesPooja Murthy, Franco Muggia
Gynecologic Oncology|September 16, 2014
Targeting HER2 in ovarian and uterine cancers: challenges and future directionsEleonora Teplinsky, Franco Muggia
Annals of Surgical Oncology|October 2, 2013
Ovarian cancer: a brief historical overview of intraperitoneal trialsMaryann Kwa, Franco Muggia
Anticancer Research|February 11, 2014
'BRCAness' and its implications for platinum action in gynecologic cancerFranco Muggia, Tamar Safra
Ecancermedicalscience|July 27, 2013
Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case reportSharan Prakash Sharma, Franco Muggia
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging treatments for ovarian cancerFranco Muggia, M Janice Lu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Systemic treatment of endometrial cancer: what is doxorubicin's role?Mendel Goldfinger, Isabela Diaz, Franco Muggia
Expert Opinion on Drug Metabolism & Toxicology|January 17, 2013
A pharmacokinetic evaluation of topotecan as a cervical cancer therapyFernanda Musa, Stephanie Blank, Franco Muggia
Anticancer Research|January 10, 2014
Platinum and other heavy metal coordinating compounds in cancer chemotherapy: overview of Verona ISPCC XIFranco Muggia, Roberto Leone, Andrea Bonetti
Recenti Progressi in Medicina|January 19, 2016
[Platinum antitumor complexes]Andrea Bonetti, Jacopo Giuliani, Franco Muggia
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesPooja Murthy, Franco Muggia
Gynecologic Oncology|September 16, 2014
Targeting HER2 in ovarian and uterine cancers: challenges and future directionsEleonora Teplinsky, Franco Muggia
Annals of Surgical Oncology|October 2, 2013
Ovarian cancer: a brief historical overview of intraperitoneal trialsMaryann Kwa, Franco Muggia
Anticancer Research|February 11, 2014
'BRCAness' and its implications for platinum action in gynecologic cancerFranco Muggia, Tamar Safra
Ecancermedicalscience|July 27, 2013
Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case reportSharan Prakash Sharma, Franco Muggia
Expert Opinion on Emerging Drugs|November 13, 2003
Emerging treatments for ovarian cancerFranco Muggia, M Janice Lu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Systemic treatment of endometrial cancer: what is doxorubicin's role?Mendel Goldfinger, Isabela Diaz, Franco Muggia
Expert Opinion on Drug Metabolism & Toxicology|January 17, 2013
A pharmacokinetic evaluation of topotecan as a cervical cancer therapyFernanda Musa, Stephanie Blank, Franco Muggia
Anticancer Research|January 10, 2014
Platinum and other heavy metal coordinating compounds in cancer chemotherapy: overview of Verona ISPCC XIFranco Muggia, Roberto Leone, Andrea Bonetti
Recenti Progressi in Medicina|January 19, 2016
[Platinum antitumor complexes]Andrea Bonetti, Jacopo Giuliani, Franco Muggia
Pageof 10